NasdaqGS:PODDMedical Equipment
Assessing Insulet (PODD) Valuation After FDA Class I Recall Of Omnipod 5 Pods
The recent FDA Class I recall of certain Omnipod 5 pods puts safety and product quality at the center of the conversation for Insulet (PODD) stock, and investors are reassessing risk.
See our latest analysis for Insulet.
The share price reaction has been sharp, with a 1 day share price return of 2.09% decline and a 7 day share price return of 8.99% decline. This extends a 30 day share price return of 16.11% decline as investors weigh the Class I recall, recent rating changes and the fully...